With almost 20 years of experience, Case Managers in Genzyme's Patient and Product Services Department provide free and voluntary care coordination, support and services to individuals living with Gaucher disease who reside in the United States. Genzyme Case Managers are healthcare professionals employed by Genzyme committed to helping individuals connect with all resources available to them.
Whether you have just been diagnosed with Type 1 Gaucher disease and are exploring treatment with Cerezyme with your doctor or you are considering resuming treatment, Genzyme Case Managers are available to assess your unique situation and answer any questions you may have, including helping you understand your insurance options for treatment with Cerezyme. Our confidential services are offered at no cost to you and are completely voluntary.
Your Call, Our Commitment
A Genzyme Case Manager is only a phone call away from answering your questions and working with you to help address your needs.
1-800-745-4447, Option 3
Monday through Friday, 8:00 AM to 6:00 PM EST
Spanish-speaking Case Managers are available, as well as interpreters for other languages.
Information you provide will always be kept confidential. Genzyme offers all Care Coordination services in compliance with patient privacy regulations (HIPAA).
Indication & Usage
Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:
- anemia (low red blood cell count)
- thrombocytopenia (low blood platelet count)
- bone disease
- hepatomegaly or splenomegaly (enlarged liver or spleen)
Important Safety Information
Approximately 15% of patients have developed immune responses (antibodies). These patients have a higher risk of an allergic reaction (hypersensitivity). Use Cerezyme® (imiglucerase for injection) carefully if you have had an allergic reaction to the product in the past. Symptoms suggestive of allergic reaction happened in 6.6% of patients, and include anaphylactoid reaction (a serious allergic reaction), itching, flushing, hives, an accumulation of fluid under the skin, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure.
Side effects related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported side effects include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Because Cerezyme therapy is administered by intravenous infusion, reactions at the site of injection may occur: discomfort, itching, burning, swelling or uninfected abscess. Cerezyme is available by prescription only. For more information, consult your physician.
Please see Full Prescribing Information (PDF).